Sleep Apnea and HCM


About this study

The purpose of this study is to determine prevalence of sleep apnea in patients with hypertrophic cardiomyopathy and assess cardiovascular risk markers.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Adults age >18 years-old with a diagnosis of HCM
  • Both sexes
  • Able to consent
  • Non-pregnant

Exclusion Criteria

  • Heart failure (symptoms and NT-proBNP >upper limit of normal for age)
  • Prior alcohol septal ablation
  • Surgical myectomy
  • Prosthetic valves
  • Current smokers or recently quit (<6 months)
  • COPD (FEV1/FVC <0.70; FEV1 <80%)
  • Known autonomic dysfunction
  • Treated sleep apnea (mandibular device, CPAP)
  • Vulnerable study population
  • Prior catheter ablation for atrial fibrillation

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Meghna Mansukhani, M.D.

Closed-enrolling by invitation

What is this? (?)
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

CPL HCM Sleep Study

More information


Publications are currently not available

Mayo Clinic Footer